Ipilimumab/nivolumab/topotecanLack of efficacy and reactivation of tuberculosis: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2021年 / 1852卷 / 1期

关键词：

D O I：

10.1007/s40278-021-94702-z

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：249 / 249

相关论文

共 50 条

[21] Ipilimumab/nivolumab/pembrolizumabHepatitis: case report
Reactions Weekly, 2020, 1834 (1) : 141 - 141
[22] Ipilimumab/nivolumab/pembrolizumabHypopituitarism: case report
Reactions Weekly, 2021, 1882 (1) : 256 - 256
[23] Ipilimumab/nivolumab/pembrolizumabMyocarditis: case report
Reactions Weekly, 2022, 1914 (1) : 266 - 266
[24] Ipilimumab/nivolumab/pembrolizumabPneumonitis: case report
Reactions Weekly, 2018, 1713 (1) : 204 - 204
[25] Ipilimumab/nivolumab/prednisoloneImmune-related myositis and lack of efficacy: case report
Reactions Weekly, 2023, 1986 (1) : 227 - 227
[26] Ipilimumab/nivolumab/pembrolizumabAlopecia areata, adrenal insufficiency and lack of efficacy: case report
Reactions Weekly, 2024, 2027 (1) : 244 - 244
[27] Ipilimumab/nivolumab/sodium chlorideHypophysitis, hypopituitarism and lack of efficacy in hyponatraemia: case report
Reactions Weekly, 2021, 1844 (1) : 240 - 240
[28] Ipilimumab/nivolumab/sorafenibSarcoidosis-like reaction and lack of efficacy: case report
Reactions Weekly, 2023, 1980 (1) : 221 - 221
[29] Ipilimumab/nivolumab/nivolumab/pembrolizumabType 1 diabetes: case report
Reactions Weekly, 2023, 1956 (1) : 286 - 286
[30] Ipilimumab/nivolumab interactionVarious toxicities: case report
Reactions Weekly, 2017, 1680 (1) : 192 - 192

← 1 2 3 4 5 →